Xu, L.
OncoMed (United States)
2 papers on CoChatORCID 0000-0001-9786-5622
Most cited papers
- Verified
A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors
Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J. V., Kapoun, A. M., Xu, L., & Munster, P. (2018) · Annals of Oncology
Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research
Cited by 138
- Verified
Phase IB Trial of the Anti‐Cancer Stem Cell DLL4‐Binding Agent Demcizumab with Pemetrexed and Carboplatin as First‐Line Treatment of Metastatic Non‐Squamous NSCLC
McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., Harris, D. L., Stagg, R. J., Kapoun, A. M., Xu, L., et al. (2018) · Targeted Oncology
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 74
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free